Ionis Pharmaceuticals to Present Data on Olezarsen for Severe Hypertriglyceridemia at Major Conferences
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Businesswire
Image: Businesswire
Ionis Pharmaceuticals will showcase new analyses from the CORE and CORE2 studies of olezarsen, aimed at treating severe hypertriglyceridemia (sHTG), at upcoming medical congresses. These findings highlight olezarsen's potential to significantly reduce triglyceride levels and the risk of acute pancreatitis, with presentations scheduled for June 2026.
- 01Olezarsen has shown a statistically significant reduction in fasting triglycerides and acute pancreatitis events in the CORE and CORE2 studies.
- 02The U.S. FDA has granted Priority Review for olezarsen, targeting a decision by June 30, 2026.
- 03Over 3 million people in the U.S. suffer from sHTG, with about 1 million at high risk for complications.
- 04The upcoming presentations will take place at the American Diabetes Association, National Lipid Association, and ENDO 2026 conferences.
- 05Olezarsen is designed to inhibit the production of apoC-III, a protein that regulates triglyceride metabolism.
Advertisement
In-Article Ad
Ionis Pharmaceuticals, based in Carlsbad, California, has announced that it will present new data analyses from its pivotal Phase 3 CORE and CORE2 studies on olezarsen, a treatment for severe hypertriglyceridemia (sHTG), at several upcoming medical conferences. These presentations will take place at the American Diabetes Association's 2026 Scientific Sessions in New Orleans, the National Lipid Association's Scientific Sessions in Chicago, and ENDO 2026, also in Chicago, all scheduled for June 2026. The data from these studies indicate that olezarsen significantly reduces fasting triglycerides and the risk of acute pancreatitis, a serious complication associated with sHTG. Sam Tsimikas, M.D., from Ionis, emphasized the urgent need for innovative treatments as current therapies provide only modest benefits. With over 3 million individuals in the U.S. affected by sHTG, the potential impact of olezarsen is substantial. The FDA has granted Priority Review for olezarsen, with a target action date of June 30, 2026, highlighting the importance of these findings for patients at risk of severe health complications.
Advertisement
In-Article Ad
The introduction of olezarsen could significantly improve treatment options for patients suffering from severe hypertriglyceridemia, potentially reducing hospitalizations due to acute pancreatitis.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of olezarsen as a treatment for severe hypertriglyceridemia?
Connecting to poll...
Read the original article
Visit the source for the complete story.